Literature DB >> 27676298

Reply to Vangala et al.: Complete inhibition of the proteasome reduces new proteasome production by causing Nrf1 aggregation.

Zhe Sha1, Alfred L Goldberg2.   

Abstract

An important adaptation of cells to proteasome inhibition is the induction of new proteasomes via the transcription factor Nrf1 [1,2], which is produced as a precursor bound to the endoplasmic reticulum (ER) through its amino terminus. Nrf1 was reported to require proteolytic processing to enter the nucleus [3]. Increased proteasome production is induced by low concentrations of proteasome inhibitors that reduce proteolysis by <50%. Surprisingly, in earlier studies we found that proteasome induction and Nrf1 processing to its shorter form (which we estimated to be 75 kDa [2]) were suppressed by high concentrations of inhibitors that markedly reduce proteasome activity [4]. This unusual bimodal concentration dependence implied that some proteasome function was necessary for Nrf1 processing. Because we found that Nrf1 processing also required ubiquitin conjugation [2], we previously proposed that Nrf1 processing is catalyzed by partially inhibited proteasomes [2]. However, Vangala et al.[5] present compelling evidence that conversion of the ER-bound Nrf1 to the shorter form, which they describe as 110 kDa, is independent of proteasomes and is not blocked by high concentrations of proteasome inhibitors. Therefore, we investigated the basis for these differing results. Here we report that we and Vangala et al. have studied the same processed form of Nrf1, the actual molecular weight of which appears to be 90-95 kDa. We confirm our earlier finding [2] that high concentrations of proteasome inhibitors suppress proteasome induction and accumulation of processed Nrf1 in soluble lysates. However, we now show that the inhibitors do so not by blocking Nrf1 processing, but instead by causing the processed Nrf1 to aggregate. Therefore, Nrf1 must be cleaved by a non-proteasomal endoprotease that we show requires ubiquitination. Finally, we provide evidence supporting the recent report that Ddi1/Ddi2 is the critical protease [6,7].
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27676298      PMCID: PMC5119528          DOI: 10.1016/j.cub.2016.08.030

Source DB:  PubMed          Journal:  Curr Biol        ISSN: 0960-9822            Impact factor:   10.834


  10 in total

1.  UBL/UBA ubiquitin receptor proteins bind a common tetraubiquitin chain.

Authors:  Yang Kang; Rebecca A Vossler; Laura A Diaz-Martinez; Nathan S Winter; Duncan J Clarke; Kylie J Walters
Journal:  J Mol Biol       Date:  2005-12-19       Impact factor: 5.469

2.  Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate.

Authors:  Alexei F Kisselev; Alice Callard; Alfred L Goldberg
Journal:  J Biol Chem       Date:  2006-02-02       Impact factor: 5.157

3.  Ddi1, a eukaryotic protein with the retroviral protease fold.

Authors:  Roy Sirkis; Jeffrey E Gerst; Deborah Fass
Journal:  J Mol Biol       Date:  2006-09-03       Impact factor: 5.469

4.  DNA-damage-inducible 1 protein (Ddi1) contains an uncharacteristic ubiquitin-like domain that binds ubiquitin.

Authors:  Urszula Nowicka; Daoning Zhang; Olivier Walker; Daria Krutauz; Carlos A Castañeda; Apurva Chaturvedi; Tony Y Chen; Noa Reis; Michael H Glickman; David Fushman
Journal:  Structure       Date:  2015-02-19       Impact factor: 5.006

5.  Proteasomal degradation is transcriptionally controlled by TCF11 via an ERAD-dependent feedback loop.

Authors:  Janos Steffen; Michael Seeger; Annett Koch; Elke Krüger
Journal:  Mol Cell       Date:  2010-10-08       Impact factor: 17.970

6.  Proteasome-mediated processing of Nrf1 is essential for coordinate induction of all proteasome subunits and p97.

Authors:  Zhe Sha; Alfred L Goldberg
Journal:  Curr Biol       Date:  2014-07-03       Impact factor: 10.834

7.  Nrf1 can be processed and activated in a proteasome-independent manner.

Authors:  Janakiram R Vangala; Franziska Sotzny; Elke Krüger; Raymond J Deshaies; Senthil K Radhakrishnan
Journal:  Curr Biol       Date:  2016-09-26       Impact factor: 10.834

8.  Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells.

Authors:  Senthil K Radhakrishnan; Candy S Lee; Patrick Young; Anne Beskow; Jefferson Y Chan; Raymond J Deshaies
Journal:  Mol Cell       Date:  2010-04-09       Impact factor: 17.970

9.  p97-dependent retrotranslocation and proteolytic processing govern formation of active Nrf1 upon proteasome inhibition.

Authors:  Senthil K Radhakrishnan; Willem den Besten; Raymond J Deshaies
Journal:  Elife       Date:  2014-01-21       Impact factor: 8.140

10.  Proteasome dysfunction triggers activation of SKN-1A/Nrf1 by the aspartic protease DDI-1.

Authors:  Nicolas J Lehrbach; Gary Ruvkun
Journal:  Elife       Date:  2016-08-16       Impact factor: 8.140

  10 in total
  14 in total

1.  An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors.

Authors:  Sondra Downey-Kopyscinski; Ellen W Daily; Marc Gautier; Ananta Bhatt; Bogdan I Florea; Constantine S Mitsiades; Paul G Richardson; Christoph Driessen; Herman S Overkleeft; Alexei F Kisselev
Journal:  Blood Adv       Date:  2018-10-09

2.  Inhibition of the Proteasome β2 Site Sensitizes Triple-Negative Breast Cancer Cells to β5 Inhibitors and Suppresses Nrf1 Activation.

Authors:  Emily S Weyburne; Owen M Wilkins; Zhe Sha; David A Williams; Alexandre A Pletnev; Gerjan de Bruin; Hermann S Overkleeft; Alfred L Goldberg; Michael D Cole; Alexei F Kisselev
Journal:  Cell Chem Biol       Date:  2017-01-26       Impact factor: 8.116

3.  Androgen receptor polyglutamine expansion drives age-dependent quality control defects and muscle dysfunction.

Authors:  Samir R Nath; Zhigang Yu; Theresa A Gipson; Gregory B Marsh; Eriko Yoshidome; Diane M Robins; Sokol V Todi; David E Housman; Andrew P Lieberman
Journal:  J Clin Invest       Date:  2018-07-23       Impact factor: 14.808

Review 4.  The Logic of the 26S Proteasome.

Authors:  Galen Andrew Collins; Alfred L Goldberg
Journal:  Cell       Date:  2017-05-18       Impact factor: 41.582

5.  PSMB2 knockdown suppressed proteasome activity and cell proliferation, promoted apoptosis, and blocked NRF1 activation in gastric cancer cells.

Authors:  Zimeng Liu; Changda Yu; Zhibing Chen; Chuanwen Zhao; Lin Ye; Chen Li
Journal:  Cytotechnology       Date:  2022-06-27       Impact factor: 2.040

Review 6.  Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy.

Authors:  Michael Basler; Marcus Groettrup
Journal:  Genes Immun       Date:  2020-08-25       Impact factor: 2.676

Review 7.  Ubiquitin-dependent regulation of transcription in development and disease.

Authors:  Kevin G Mark; Michael Rape
Journal:  EMBO Rep       Date:  2021-03-28       Impact factor: 8.807

8.  Mammalian Ddi2 is a shuttling factor containing a retroviral protease domain that influences binding of ubiquitylated proteins and proteasomal degradation.

Authors:  Galen Andrew Collins; Zhe Sha; Chueh-Ling Kuo; Beyza Erbil; Alfred L Goldberg
Journal:  J Biol Chem       Date:  2022-03-28       Impact factor: 5.486

9.  Inhibition of NGLY1 Inactivates the Transcription Factor Nrf1 and Potentiates Proteasome Inhibitor Cytotoxicity.

Authors:  Frederick M Tomlin; Ulla I M Gerling-Driessen; Yi-Chang Liu; Ryan A Flynn; Janakiram R Vangala; Christian S Lentz; Sandra Clauder-Muenster; Petra Jakob; William F Mueller; Diana Ordoñez-Rueda; Malte Paulsen; Naoko Matsui; Deirdre Foley; Agnes Rafalko; Tadashi Suzuki; Matthew Bogyo; Lars M Steinmetz; Senthil K Radhakrishnan; Carolyn R Bertozzi
Journal:  ACS Cent Sci       Date:  2017-10-25       Impact factor: 14.553

10.  DDI2 Is a Ubiquitin-Directed Endoprotease Responsible for Cleavage of Transcription Factor NRF1.

Authors:  A Barbara Dirac-Svejstrup; Jane Walker; Peter Faull; Vesela Encheva; Vyacheslav Akimov; Michele Puglia; David Perkins; Sandra Kümper; Suchete S Hunjan; Blagoy Blagoev; Ambrosius P Snijders; David J Powell; Jesper Q Svejstrup
Journal:  Mol Cell       Date:  2020-06-09       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.